Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Lisi Lim

Citation

Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256

Authors

L.E. Lim1, D.L. Chan2, D. Thomas3, D.K. Wyld4, G. Cehic5, W. Macdonald6, Y.T. Du5, G. Tincknell3, A. Kuchel4, N. Pavlakis2, D. Bailey2, A. Davis2, E. Segelov1

Author affiliations

  • 1 Medical Oncology, Monash Health, 3165 - Melbourne/AU
  • 2 Medical Oncology, Royal North Shore Hospital, 2065 - St Leonards/AU
  • 3 Medical Oncology, St George Hospital, 2217 - Kogarah/AU
  • 4 Medical Oncology, Royal Brisbane and Women's Hospital, 4029 - Herston/AU
  • 5 Nuclear Medicine, The Queen Elizabeth Hospital, 5011 - Woodville South/AU
  • 6 Nuclear Medicine, Fiona Stanley Hospital, 6150 - Murdoch/AU
More

Resources

Abstract 1543

Background

Peptide receptor radionuclide therapy (PRRT) is an established treatment modality for advanced midgut neuroendocrine tumours (NET) (1), based on the presence of somatostatin receptors (SSTR). This therapy should be effective for SSTR expressing NETs from all sites of origin. SSTR expression correlates with grade, with higher expression seen in lower grade disease (2). No trials of PRRT have been undertaken in patients with typical carcinoid (TC) or atypical carcinoid (AC) of bronchial origin. Most guidelines for bronchopulmonary NET either do not comment on PRRT or acknowledge lack of data. However, small retrospective case series, reporting 11 to 34 patients, suggest potential benefit from lutetium (177Lu)-based PRRT (3-10).

Methods

We undertook a retrospective chart review of patients with TC and AC who had received at least one dose of lutetium-based PRRT in six major NET centres across Australia. Demographics, histopathology and information on clinical course were collected.

Results

Data was collected from 53 patients treated across six centres between January 2002 and 2019. Patient details from four centres are presented in the table. Each of these four centres had 1, 8, 9 and 15 eligible patients respectively. Of these 33 patients, 22 are still alive, with the duration of follow up post the first cycle of PRRT ranging from 3 to 67 months. Analysis of the whole cohort for treatment, dose, response, patient and disease outcomes will be presented.Table:

1401P Clinical characteristics (Four centres in South Australia, Victoria, New South Wales)

GenderNumber (n = 33)
Male22 (67%)
Female11 (33%)
Age (years)
<7021 (64%)
≥7012 (36%)
Histopathology
TC12 (36%)
AC21 (64%)
Current status
Alive22 (67%)
Dead11 (33%)

Conclusions

This is the largest series of patients with bronchial carcinoid treated with PRRT to be reported to date. Evaluation of lutetium-based PRRT in a prospective clinical trial is of interest to validate its efficacy as a therapeutic option.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Monash Health.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings